Evidence map›Paper›PMID 40191833›Full record

ArticleContact in context2025

Rapid Quality Assessment of Ceftriaxone Using Near-Infrared Spectroscopy.

James T Isaacs, Philip J Almeter, Aaron N Hunter, Thomas A Lyman, Stephanie P Zapata, Bradley S Henderson, Seth A Larkin, Eleonora Hasani, Uiyeol Yoon, Adler Crumrin and 9 more

Abstract read
In one paragraph

Article in Contact in context, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

James T IsaacsDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Philip J AlmeterDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Aaron N HunterDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Thomas A LymanDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Stephanie P ZapataDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Bradley S HendersonDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Seth A LarkinDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Eleonora HasaniDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Uiyeol YoonDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Adler CrumrinDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Jerod SmithDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Spencer PergremDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Ashton PlymaleDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Bailee RamnesDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Joshua D MelsonDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Jeffrey W ReynoldsDepartment of Finance, University of Kentucky HealthCare, Lexington, KY.
Ryan W NasemanDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Thomas L PlattDepartment of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536.
Robert A LodderDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536.ORCID 0000-0001-6133-7561

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
NCATS NIH HHS UL1 TR001998
6 · The paper itself

Abstract

Ceftriaxone for injection, USP is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is a white to yellowish crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The color of ceftriaxone sodium solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used. Each vial contains ceftriaxone sodium equivalent to 250 mg, 500 mg, 1 gram or 2 grams of ceftriaxone activity. Ceftriaxone sodium contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity. Intra-lot variability was detected in the spectra of 6 vials of ceftriaxone sampled from one lot. One of the vials was more than 8.3 multidimensional SDs away from the center of the cluster of the other 5 vials from the same lot, suggesting that the manufacturing process may not be in a state of control. Interlot variability was detected between two lots of the drug using a subcluster detection test (r

Identifiers

PMID40191833
PMCPMC11970922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.